Three-year surveillance study of nosocomial bacterial resistance in Argentina

International Journal of Infectious Diseases

Volumn 4, Issue 2, 2000, Pages 85-90

  Bantar, Carlos ^a,d,ac   Famiglietti, Angela ^a,i   Goldberg, Mirta ^a   Altschuler, M ^a,b   Bardi, L ^c   Casellas, J M ^a,e   Castro, H ^f   Couto, E ^a   Di Rocco, P ^a   Galas, M ^a   Gutkind, G ^a   Marin M ^a   Nicola, F ^a   Pasteran F ^a   Quinteros, M ^a,u   Radice, M ^a   Rossi, A ^a   Soloaga, R ^a   Durany, D ^g   Entizne, A ^h   Fernandez, A ^j   Fernandez Canigia, L ^k   Hoffman, M ^l   Latorraga, C ^m   Monterisi, A ⁿ   Moreno, N ^o   Navarro, R ^p   Pantozzi, F ^q   Pariz De Baeza, A ^r   Perez, S ^s   Posse, G ^t   Schuster, M ^v   Scilingo, V ^w   Soriano, S ^x   Sparo, M ^y   Sutich, E ^z   Tome G ^aa   Vergara, M ^ab   more..

^a Soc Argentina de Bacteriologia   (Argentina)

^b Children Hospital 'Superiora Sor Maria Ludovica'   (Argentina)

^c Servicio de Clínica Médica   (Argentina)

^d CEMIC   (Argentina)

^e Sanatorio San Lucas   (Argentina)

^f Hospital Marcial Quiroga   (Argentina)

^g H Area Programada   (Argentina)

^h Leonidas Lucero Municipal Hospital   (Argentina)

ⁱ H de Clínicas   (Argentina)

^j HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^k Alemán Hospital   (Argentina)

^l H Tornú   (Argentina)

^m Sanatorio Greyton   (Argentina)

ⁿ Hospital Nacional de Clinicas   (Argentina)

^o Centeno   (Argentina)

^p Lab Central de Análisis   (Argentina)

^q H Italiano   (Argentina)

^r Sanatorio Privado del Sur   (Argentina)

^s IACA Laboratories   (Argentina)

^t Sanatorio Adventista   (Argentina)

^u Muñiz Hospital   (Argentina)

^v Servicio de Nefrología   (Argentina)

^w Fundacion Centro de Estudios Infectologicos   (Argentina)

^x Sect Bacteriologia y Serv I   (Argentina)

^y H Santamarina   (Argentina)

^z H Centenario   (Argentina)

^aa DIF   (France)

^ab Sanatorio Nosiglia   (Argentina)

^ac NONE   (Argentina)

more..

Author keywords

Nosocomial infections; Resistance; Surveillance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; NITROFURANTOIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; HEALTH SURVEY; HOSPITAL INFECTION; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN;

EID: 6744259046     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(00)90099-7     Document Type: Article

References (25)

1. Shlaes DM, Gerding DN, Jonh JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-590.
2. John J, Fishman N. Programatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24:471-485.
3. MacGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15:478-483.
4. Ballow CH, Schentag JJ. Trend in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15:37S-45S.
5. Archibald L, Phillips L, Monnet D, Mac Gowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215.
6. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999; 5:18-27.
7. Casellas JM, Guzman-Blanco M, Pinto ME. The sleeping giant: antimicrobial resistance. Infect Dis Clin North Am 1994; 8:29-45.
8. Murray P, Baron E, Pfaller M, Tenover F, Yolken R, eds. Manual of clinical microbiology, 6th ed. Washington DC: American Society for Microbiology, 1995.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6, 6th ed. Wayne. PA: NCCLS, 1999.
10. Polk R. Optimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999; 29:264-274.
11. Levy SB, ed. The antibiotic paradox: how the miracle drugs are destroying the miracle. 1st ed. New York: Plenum Press, 1992.
12. Bantar C, Nicola F, Arenoso H, et al. Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-β-lactamase inhibitor combination, against Escherichia coli. Antimicrob Agents Chemother 1999; 43:1503-1504.
13. Casellas JM, Goldberg M. Incidence of strains producing extended spectrum beta-lactamases in Argentina. Infection 1989; 17.434-436.
14. Bauernfeind A, Casellas JM, Goldberg M, et al. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection 1992, 20:158-163.
15. Bauernfeind A, Stemplinger I, Jungwirth R, et al. Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase. Antimicrob Agents Chemother 1996; 40:616-620.
16. Galas M, Rapoport M, Pasterán F, et al. High distribution of CTX-M-2 β-lactamase among Klebsiella spp isolates in an Argentinean extended-spectrum β-lactamase (ESBLA) surveillance program. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco: California, USA, September 26-29, 1999.
17. Galas M, Pasterán F, Melano R, et al. Unusual distribution of enzymatic resistance to third-generation cephalosporin (TGC) in E. coli in Argentina. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, California, USA, September 24-27, 1998.
18. Pasteran F, Melano R, Galas M, et al. High proportion of extended spectrum β-lactamases (ESBLA) among AMP-C producers enterobacteria in Argentina. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, California, USA, September 26-29, 1999.
19. Carmeli Y, Troillet N, Eliopoulos G, Samore M. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-1382.
20. Pace J, Rossi A, Mollerach M, et al. Resistance mechanisms associated to imipenem-resistant Pseudomonas aeruginosa in Argentina. Presented at the 3rd Intenational Conference of the Hospital Infection Society. London, United Kingdom, September 4-8, 1994.
21. Brown S, Bantar S, Young H-K, Amyes S. Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2. Lancet 1998; 350:186-187.
22. Fridkin S, Edwards JR, Pichette SC, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999; 28:1119-1125.
23. Corso A, Santos-Sanches I, Aires de Sousa M, Rossi A, de Lencastre H. Spread of a methicillin-resistant and multiresistant epidemic clone of Staphylococcus aureus in Argentina. Microb Drug Resist 1999; 4:277-288.
24. Bantar C, Rojas A, Relloso S, Smayevsky J, Bianchini H Identification of Enterococcus spp in clinical samples. Incidence of high-level resistance to aminoglycosides. Infect Microbiol Clin 1991; 3:84-89.
25. Marín M, Mera J, Arduino R, et al. First report of vancomycin-resistant Enterococcus faecium isolated in Argentina Clin Infect Dis 1998; 26:235-236.